Development of acute and subacute toxicity with the serotonin transporter radiopharmaceutical, ADAM

Kang Wei Chang, Chia Chieh Chen, Shih Ying Lee, Lie Hang Shen, Hsin Ell Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

It is predicted that depression will become the most common neurological disease in the new millennium. Its incidence is currently about 3% of diseases worldwide. Serotonin is an essential neurotransmitter for the central and peripheral nervous systems and plays a crucial role in neuropsychiatric disorders. 123I-labeled ADAM was developed to facilitate an early diagnosis of serotonin transporter (SERT) abnormalities in the brain. Many studies have confirmed that the binding of this radiotracer to SERTs is associated with depression. The aim of this study was to evaluate the acute and subacute toxicity of ADAM and to determine its no observed adverse effect level (NOAEL) by administering it via intravenous injection to Sprague-Dawley rats for 14 consecutive days. None of the animals died, and no treatment-related clinical signs were observed. Urinalysis, hematology, and clinical chemistry analysis revealed that daily administration of ADAM (2-2- dimethylaminomethylphenylthio-5-iodophenylamine) for 2 weeks had no toxicological effects. It is concluded that ADAM exerts no adverse toxic effects on this animal model. The NOAEL was 155μg/kg/day.

Original languageEnglish
Pages (from-to)393-402
Number of pages10
JournalDrug and Chemical Toxicology
Volume33
Issue number4
DOIs
Publication statusPublished - Oct 1 2010
Externally publishedYes

Fingerprint

No-Observed-Adverse-Effect Level
Serotonin Plasma Membrane Transport Proteins
Radiopharmaceuticals
Toxicity
Animals
Clinical Chemistry
Urinalysis
Poisons
Peripheral Nervous System
Neurology
Hematology
Intravenous Injections
Toxicology
Neurotransmitter Agents
Sprague Dawley Rats
Rats
Early Diagnosis
Brain
Serotonin
Central Nervous System

Keywords

  • ADAM
  • Depression
  • Toxicity

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Public Health, Environmental and Occupational Health
  • Health, Toxicology and Mutagenesis
  • Chemical Health and Safety

Cite this

Development of acute and subacute toxicity with the serotonin transporter radiopharmaceutical, ADAM. / Chang, Kang Wei; Chen, Chia Chieh; Lee, Shih Ying; Shen, Lie Hang; Wang, Hsin Ell.

In: Drug and Chemical Toxicology, Vol. 33, No. 4, 01.10.2010, p. 393-402.

Research output: Contribution to journalArticle

Chang, Kang Wei ; Chen, Chia Chieh ; Lee, Shih Ying ; Shen, Lie Hang ; Wang, Hsin Ell. / Development of acute and subacute toxicity with the serotonin transporter radiopharmaceutical, ADAM. In: Drug and Chemical Toxicology. 2010 ; Vol. 33, No. 4. pp. 393-402.
@article{66bf8a4213044430948af10a3047392d,
title = "Development of acute and subacute toxicity with the serotonin transporter radiopharmaceutical, ADAM",
abstract = "It is predicted that depression will become the most common neurological disease in the new millennium. Its incidence is currently about 3{\%} of diseases worldwide. Serotonin is an essential neurotransmitter for the central and peripheral nervous systems and plays a crucial role in neuropsychiatric disorders. 123I-labeled ADAM was developed to facilitate an early diagnosis of serotonin transporter (SERT) abnormalities in the brain. Many studies have confirmed that the binding of this radiotracer to SERTs is associated with depression. The aim of this study was to evaluate the acute and subacute toxicity of ADAM and to determine its no observed adverse effect level (NOAEL) by administering it via intravenous injection to Sprague-Dawley rats for 14 consecutive days. None of the animals died, and no treatment-related clinical signs were observed. Urinalysis, hematology, and clinical chemistry analysis revealed that daily administration of ADAM (2-2- dimethylaminomethylphenylthio-5-iodophenylamine) for 2 weeks had no toxicological effects. It is concluded that ADAM exerts no adverse toxic effects on this animal model. The NOAEL was 155μg/kg/day.",
keywords = "ADAM, Depression, Toxicity",
author = "Chang, {Kang Wei} and Chen, {Chia Chieh} and Lee, {Shih Ying} and Shen, {Lie Hang} and Wang, {Hsin Ell}",
year = "2010",
month = "10",
day = "1",
doi = "10.3109/01480540903530753",
language = "English",
volume = "33",
pages = "393--402",
journal = "Drug and Chemical Toxicology",
issn = "0148-0545",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Development of acute and subacute toxicity with the serotonin transporter radiopharmaceutical, ADAM

AU - Chang, Kang Wei

AU - Chen, Chia Chieh

AU - Lee, Shih Ying

AU - Shen, Lie Hang

AU - Wang, Hsin Ell

PY - 2010/10/1

Y1 - 2010/10/1

N2 - It is predicted that depression will become the most common neurological disease in the new millennium. Its incidence is currently about 3% of diseases worldwide. Serotonin is an essential neurotransmitter for the central and peripheral nervous systems and plays a crucial role in neuropsychiatric disorders. 123I-labeled ADAM was developed to facilitate an early diagnosis of serotonin transporter (SERT) abnormalities in the brain. Many studies have confirmed that the binding of this radiotracer to SERTs is associated with depression. The aim of this study was to evaluate the acute and subacute toxicity of ADAM and to determine its no observed adverse effect level (NOAEL) by administering it via intravenous injection to Sprague-Dawley rats for 14 consecutive days. None of the animals died, and no treatment-related clinical signs were observed. Urinalysis, hematology, and clinical chemistry analysis revealed that daily administration of ADAM (2-2- dimethylaminomethylphenylthio-5-iodophenylamine) for 2 weeks had no toxicological effects. It is concluded that ADAM exerts no adverse toxic effects on this animal model. The NOAEL was 155μg/kg/day.

AB - It is predicted that depression will become the most common neurological disease in the new millennium. Its incidence is currently about 3% of diseases worldwide. Serotonin is an essential neurotransmitter for the central and peripheral nervous systems and plays a crucial role in neuropsychiatric disorders. 123I-labeled ADAM was developed to facilitate an early diagnosis of serotonin transporter (SERT) abnormalities in the brain. Many studies have confirmed that the binding of this radiotracer to SERTs is associated with depression. The aim of this study was to evaluate the acute and subacute toxicity of ADAM and to determine its no observed adverse effect level (NOAEL) by administering it via intravenous injection to Sprague-Dawley rats for 14 consecutive days. None of the animals died, and no treatment-related clinical signs were observed. Urinalysis, hematology, and clinical chemistry analysis revealed that daily administration of ADAM (2-2- dimethylaminomethylphenylthio-5-iodophenylamine) for 2 weeks had no toxicological effects. It is concluded that ADAM exerts no adverse toxic effects on this animal model. The NOAEL was 155μg/kg/day.

KW - ADAM

KW - Depression

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=77956139062&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956139062&partnerID=8YFLogxK

U2 - 10.3109/01480540903530753

DO - 10.3109/01480540903530753

M3 - Article

C2 - 20550426

AN - SCOPUS:77956139062

VL - 33

SP - 393

EP - 402

JO - Drug and Chemical Toxicology

JF - Drug and Chemical Toxicology

SN - 0148-0545

IS - 4

ER -